Skip to main content
SpringerLink
Log in

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

TNP-740, minocycline, suramin and genistein have demonstrated antiangiogenic activity in various experimental systems. The effect of these agents alone and in two agent combinations on the number of intratumoral vessels and response to cytotoxic anticancer therapies was assessed in animals bearing the Lewis lung carcinoma. Treatment with each of the antiangiogenic agents alone and in two agent combinations decreased the number of intratumoral vessels visualized by CD31 or Factor VIII staining to 30% to 50% of the number in the untreated control tumors. In general, the antiangiogenic agents are more effective adjuvants to cytotoxic therapies when used as two agent combinations than as single agents. The most effective antiangiogenic combinations were: TNP-470/minocycline > TNP-470/genistein > TNP-470/suramin. The increases in the response of the primary tumor to cyclophosphamide, adriamycin, CDDP, BCNU, x-rays or 5-fluorouracil and the lung metastases occur to about the same level with the addition of antiangiogenic agents to the therapies. With the treatment combination TNP-470/minocycline/cyclophosphamide 40% of the animals were cured. The results of these studies indicate that antiangiogenic agents can be very useful additions to treatment regimens for solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alvarez Sotomayor E, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei III E: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30:377–384, 1992

    Google Scholar 

  2. Teicher BA, Alvarez Sotomayor E, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704, 1992

    Google Scholar 

  3. Teicher BA, Alvarez Sotomayor E, Huang ZD, Ara G, Holden S, Khandekar V, Chen Y-N: β-Cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 33:229–238, 1993

    Google Scholar 

  4. Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen Y-N, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with antiangiogenic agents. Int J Cancer 57:920–925, 1994

    Google Scholar 

  5. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Ca Res Trtmt 36:227–236, 1995

    Google Scholar 

  6. Teicher BA, Dupuis NP, Robinson M, Emi Y, Goff D: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncology Res 7(5):237–243, 1995

    Google Scholar 

  7. Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN: Antiangiogenic agents can increase tumor oxygenation and responses to radiation therapy. Radiat Oncol Invest 2:269–276, 1995

    Google Scholar 

  8. Brem H, Ingber D, Blood CH, Bradley D, Urioste S, Folkman J: Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 42:439–441, 1991

    Google Scholar 

  9. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamura T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557, 1990

    Google Scholar 

  10. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212–216, 1994

    Google Scholar 

  11. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54:2073–2076, 1994

    Google Scholar 

  12. Yamamoto T, Sudo K, Fujita T: Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 14:1–4, 1994

    Google Scholar 

  13. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J: Potent antiangiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070–1976, 1991

    Google Scholar 

  14. Takayamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL: Inhibition of angiogenesis and growth of human nerve sheath tumors by AGM-1470. J Neurosurg 78:470–476, 1993

    Google Scholar 

  15. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. Cancer Res 53:2566–2570, 1993

    Google Scholar 

  16. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa T, Toguchi H: Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exper Ther 264(1):469–474, 1993

    Google Scholar 

  17. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(Chloroacetylcarbamoyl)fumagillin (TNP-470; AGM-1470). Cancer Res 53:4262–4267, 1993

    Google Scholar 

  18. Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3:525–528, 1993

    Google Scholar 

  19. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53:5233–5236, 1993

    Google Scholar 

  20. Schoof DD, Obando JA, Cusack Jr. JC, Goedegebuure PS, Brem H, Eberlein TJ: The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 55:630–635, 1993

    Google Scholar 

  21. Tsujimoto H, Hagiwara A, Osaki K, Ohyama T, Sakakibara T, Sakuyama A, Ohgaki M, Imanishi T, Watanabe N, Yamazaki J, Shirasu M, Sakakura C, Shimotsuma M, Takahashi T: Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice. Anti-Cancer Drugs 6:438–442, 1995

    Google Scholar 

  22. Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi J-P: Disposition and metabolism of the angiogenic moderator O-(chloracetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 55:3036–3042, 1995

    Google Scholar 

  23. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51:672–675, 1991

    Google Scholar 

  24. Takano S, Gately S, Neville M, Herblin WF, Gross JL, Brem S: Suramin, an inhibitor of angiogenesis, suppresses endothelial cell growth, migration and plasminogen activator activity. Proc Amer Assoc Cancer Res 34:74, 1993

    Google Scholar 

  25. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68:932–938, 1993

    Google Scholar 

  26. Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499–508, 1989

    Google Scholar 

  27. Yayon A, Klagsbrun M: Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin. Proc Nat Acad Sci USA 87:5346–5350, 1990

    Google Scholar 

  28. Firsching A, Nickel P, Mora P, Allolio B: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55:4957–4961, 1995

    Google Scholar 

  29. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453–462, 1995

    Google Scholar 

  30. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654–2660, 1994

    Google Scholar 

  31. Barnes S, Grubbs C, Setchell KDR, Carlson J: Soybeans inhibit mammary tumor in models of breast cancer. In: Pariza M, Liss AR (eds), Mutagens and carcinogens in the diet. Wiley-Liss. New York, 1990, pp 239–253

    Google Scholar 

  32. Messina M, Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83:541–546, 1991

    Google Scholar 

  33. Wei H, Wei L, Frenkel K, Bowen R, Barnes S: Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20:1–12, 1993

    Google Scholar 

  34. Zwiller J, Sassone-Corsi P, Kakazu K, Boyton AL: Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor. Oncogene 6:219–221, 1991

    Google Scholar 

  35. Linassier C, Pierre M, Le Peco J-B, Pierre J: Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol 39:187–193, 1990

    Google Scholar 

  36. Yamashita Y, Kawada S, Nakano H: Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39:737–744, 1990

    Google Scholar 

  37. Constantinou A, Kiguchi K, Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50:2618–2624, 1990

    Google Scholar 

  38. Kondo K, Watanabe T, Oishi M: Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of toposiomerases. Cancer Res 51:5398–5404, 1991

    Google Scholar 

  39. Watanabe T, Kondo K, Oishi M: Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases. Cancer Res 51:764–768, 1991

    Google Scholar 

  40. Peterson G, Barnes S: Genistein inhibition of the growth of human breast cancer cells: independent from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179:661–667, 1991

    Google Scholar 

  41. McCabe Jr. MJ, Orrenius S: Genistein induces apoptosis in immature human thymocytes by inhibiting toposiomerase-II. Biochem Biophys Res Commun 194(2):944–950, 1993

    Google Scholar 

  42. O'Dell TJ, Kandel ER, Grant SGN: Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Lett Nature 353:558–560, 1991

    Google Scholar 

  43. Kanatani Y, Kasukabe T, Hozumi M, Motoyoshi K: Genistein exhibits preferential cytotoxicity to a leukemogenic variant but induces differentiation of a non-leukemogenic variant of the mouse monocytic leukemia Mm cell line. Leuk Res 17(10):847–853, 1993

    Google Scholar 

  44. Markovits J, Junqua S, Goldwasser F, Venuat A-M, Luccioni C, Beaumatin J, Saucier J-M, Bernheim A, Jacquemin-Sablon A: Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II β isoform. Biochem Pharmacol 50(2):177–186, 1995

    Google Scholar 

  45. Supko JG, Malspeis L: Plasma pharmacokinetics of genistein in mice. Int J Oncol 7:847–854, 1995

    Google Scholar 

  46. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Nat Acad Sci USA 90:2690–2694, 1993

    Google Scholar 

  47. Weidner N, Folkman J, Pozza F, Pierantonio B, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992

    Google Scholar 

  48. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. New Eng J Med 324:1–8, 1991

    Google Scholar 

  49. Grunt TW, Lametschwadtner A, Karrer K: The characteristic structural feature of the blood vessels of the Lewis lung carcinoma. Scan Electron Microsc 11:575–589, 1986

    Google Scholar 

  50. Grunt TW, Lametschwadtner A, Karrer K, Staindl O: The angioarchitecture of the Lewis lung carcinoma in laboratory mice. Scan Electron Miscrosc 11:557–574, 1986

    Google Scholar 

  51. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. Med Intell 18:1197–1200, 1989

    Google Scholar 

  52. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr 118:59–66, 1991

    Google Scholar 

  53. Nanus DM, Schmitz-Dräger BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597–1599, 1993

    Google Scholar 

  54. Dickson RB, Lippman ME: Molecular determinants of growth, angiogenesis, and metastases in breast cancer. Semin Oncol 19:286–298, 1992

    Google Scholar 

  55. Aaltoma S, Lipponen P: Prognostic factors in breast cancer (review). Int J Oncol 1:153–159, 1992

    Google Scholar 

  56. Gasparini G, Gullick WJ, Bevilacqua P, Pozza F, Lemoine NR, Meli S, Boracchi P, La Malfa G, Weidner N: Pathobiological characteristics of the first primary and risk of metachronous contralateral invasive breast carcinoma: clinical implications. Int J Oncol 2:781–790, 1993

    Google Scholar 

  57. Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A(8):1141–1145, 1993

    Google Scholar 

  58. Teicher BA, Holden SA, Ara G, Dupuis N, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 61(5):732–737, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 021150, USA

    Yoshihiro Kakeji & Beverly A. Teicher

Authors
  1. Yoshihiro Kakeji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beverly A. Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kakeji, Y., Teicher, B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15, 39–48 (1997). https://doi.org/10.1023/A:1005718628223

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005718628223

Search

Navigation